Table 2.
Outcomes
| Category | No. of Patients | Response Rate | % | CR/CRu | % | Median TTF (months) | Median OS (months) |
|---|---|---|---|---|---|---|---|
| R-CHOP* | 56 | 39 | 70 | 11 | 20 | 34.2 | NR |
| RIT† | 50 | 32 | 64 | 23 | 46 | 30.8 | NR |
| Age, years | |||||||
| ≤ 65 | 35 | 30 | 86 | 21 | 60 | 35.3 | NR |
| > 65 | 21 | 16 | 76 | 10 | 48 | 24.6 | 68.5 |
| P | .48 | .41 | .33 | .08 | |||
| IPI | |||||||
| 0-2 | 29 | 25 | 86 | 20 | 69 | 31.5 | NR |
| 3-5 | 26 | 20 | 77 | 10 | 38 | 34.6 | NR |
| P | .49 | .03 | .74 | .87 | |||
| MIPI baseline | |||||||
| Low | 28 | 28 | 100 | 17 | 61 | 36.4 | NR |
| Intermediate | 15 | 11 | 73 | 8 | 53 | 24.6 | NR |
| High | 12 | 6 | 50 | 5 | 42 | 10.2 | 65.6 |
| P | < .001 | .53 | .12 | .01 | |||
| Circulating lymphoma cells/μL | |||||||
| ≤ 5,000 | 49 | 41 | 84 | 28 | 57 | 34.5 | NR |
| > 5,000 | 7 | 5 | 71 | 3 | 43 | 12.6 | NR |
| P | .60 | .69 | .34 | .58 | |||
Abbreviations: CR, complete response; CRu, complete response–unconfirmed; IPI, International Prognostic Index; MIPI, mantle-cell lymphoma IPI; NR, not reached; OS, overall survival; PS, performance status; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; RIT, radioimmunotherapy; TTF, time to treatment failure.
*
Response rate and CR/CRu were evaluated after fourth-cycle R-CHOP compared with baseline measurements. TTF and OS were calculated from study registration.
†
Response rate and CR/CRu were evaluated 3 months after RIT and compared with pre-RIT measurements. TTF and OS were calculated from RIT start.